Insilico Medicine
Coverage of Insilico Medicine in the Nexus archive.
- Insilico Medicine, SK Biopharmaceuticals strike $2.5B AI drug discovery deal targeting neuroimmune therapies
Insilico Medicine and SK Biopharmaceuticals signed a $2.5B partnership to develop neuroimmune therapies using AI-driven drug discovery. Insilico will design candidates via its Pharma.AI platform, while SK Biopharmaceuticals handles late-stage development and commercialization. The deal includes potential milestone payments and royalties, marking Insilico's largest Asia-Pacific collaboration.
- Insilico teams up with US firm to build AI models predicting disease decades ahead
Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage advancements in AI and the growing $5.3 trillion global longevity market driven by aging populations.
- Insilico teams up with US firm to build AI models predicting disease decades ahead
Insilico Medicine, a Hong Kong-listed AI drug-discovery company, has partnered with US-based Human Longevity to develop large-scale AI foundation models capable of predicting diseases like cancer decades before symptoms appear. The collaboration aims to leverage the growing global longevity market, valued at $5.3 trillion.